Jörg-Michael Rupp: I will always grasp with both hands any opportunity where I can meet patients, as well as those who treat them
Jörg-Michael Rupp, Head of Roche Pharma International, shared on LinkedIn:
“I will always grasp with both hands any opportunity where I can meet patients, as well as those who treat them. Recently I was fortunate enough to do just this when I visited the Institut National d’Oncologie in Morocco, a humbling and unforgettable experience.
Coinciding with Breast Cancer Awareness Month, it felt only right that oncology remained a key focus of my time in this diverse country. Another highlight was learning more about Roche’s partnership with the Lalla Salma Foundation. The Foundation is already making significant progress in improving the quality of cancer management and ensuring that all Moroccan patients have access to a high standard of cancer care. This includes early detection projects in breast and cervical cancer, and a tobacco control programme delivered in partnership with the Ministry of Health.
In our ongoing partnership with the Lalla Salma Foundation we also contribute to achieving the objectives of the National Cancer Control Plan through support of awareness campaigns, medical training and cancer registries. The numbers speak for themselves; every year, 1,500 patients benefit from innovative cancer therapies.
Alongside my conversations with healthcare professionals, patients and policymakers I have also enjoyed interacting with my colleagues at Roche Morocco. Our team in Morocco responded with strength and courage after last month’s earthquake, supporting one another, our partners and patients during this difficult time. This is yet another example of the power of partnerships; only through working together can we truly make a difference for patients across the globe.”
Source: Jörg-Michael Rupp/LinkedIn
-
17:28 29/11JeeSuk Chang: A multi-center trial - great efforts from the KROG team
-
17:00 29/11Maite Bourlon: Access to novel drugs for metastatic renal cell carcinoma is an unmet need in the Mexican population
-
23:17 28/11Manni Mohyuddin: Current trials must have observation/surveillance as control arm
-
23:04 28/11Juan P. Alderuccio: Our approach to secondary CNS involvement by aggressive lymphomas
-
17:17 27/11Vivek Subbiah: Treatment patterns and overall survival (OS) in patients with advanced NSCLC in three countries between 2011 and 2020
-
17:43 28/11Michele Carbone: The world is full of good, honest, nice people
-
17:24 28/11Jessica Clerc: Celebrating 90 Years of Excellence and Dedication in Cancer Care!
-
17:44 25/11Carlos Pedraz: Congratulations, Dr. Rafael Rosell for the very well deserved 2023 ISLB Lifetime Achievement Award
-
17:10 25/11100 Influential Celebrities in Oncology: The 2023 Edition – Part 4
-
13:34 24/11"Bald for a Cause" initiative - UWC Dilijan College
-
17:34 28/11The International Association of Cancer Registries annual conference - IARC
-
18:05 26/11Submit your abstract by 13 February for ESMO-Breast-24 - ESMO
-
17:58 26/11Lisa A. Lacasse: My sincere gratitude to the ACS CAN team, our incredible volunteers, and supporters for another outstanding year
-
16:47 16/11How social determinants can influence a patient’s ability to stay in treatment - ASCO
-
13:22 16/11SIOP Europe Student Summer School for Paediatric Oncology
-
17:25 29/11NIH Director’s Early Independence Award supports junior scientists to launch independent careers - National Cancer Institute
-
17:07 29/11Santhosh Kumar Devadas: I’m starting a new position as a Professor of Medical Oncology and Chief of Bone Marrow Transplant at Ramaiah Memorial Hospital and Ramaiah Medical College
-
16:48 27/11CRCHD seeks motivated scientists to serve as Program Directors - NCI Disparities
-
16:25 27/11Luisa Basset completed a fruitful nine-year tenure on the CCI board of trustees - Childhood Cancer International
-
18:14 26/11Tristan Knight: Attention hematology / oncology and pediatric hematology / oncology fellows